MOLECULAR PARTNERS AG
MOLN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MOLN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MOLN
Molecular Partners AG is a clinical-stage biotechnology company developing a pipeline of DARPin-based targeted oncology therapeutics, including CD3 T-cell engagers and Radio DARPin Therapies, with no approved products to date.
Key risk: No approved products
Market Cap
$172.4M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
Tracking 4 clinical trials for MOLECULAR PARTNERS AG.
Molecular Partners AG is a clinical-stage biotechnology company developing a pipeline of DARPin-based targeted oncology therapeutics, including CD3 T-cell engagers and Radio DARPin Therapies, with no approved products to date.
- Molecular Partners AG is advancing three key product candidates: MP0533 (CD3 T-cell engager for AML), MP0317 (oncology combination therapy), and MP0712 (DLL3-targeting Radio DARPin Therapy) [sec · filed 2026-03-12].
- The company reported cash and equivalents of $82.7M as of 2025-12-31, with shareholders' equity of $235.2M and total debt of $10.7M [sec].
- Molecular Partners has incurred significant losses since inception and expects to continue incurring losses, with no product candidates having received marketing approval from the FDA or other regulatory authorities [sec · filed 2025-03-06].
- The company's cash runway is estimated to fund operations into 2028, based on assumptions that may prove incorrect [sec · filed 2026-03-12].
What works
- The company has a diversified pipeline of DARPin-based candidates targeting multiple oncology pathways, including CD3 engagement and radio-therapy, which may reduce single-asset risk [sec · filed 2026-03-12].
- Molecular Partners has sufficient cash ($82.7M as of 2025-12-31) to fund operations into 2028, providing a multi-year development runway [sec · filed 2026-03-12].
- The platform approach allows for potential expansion of the pipeline and partnerships, with a focus on targeted therapeutics that may offer differentiated mechanisms [sec · filed 2025-03-06].
What to weigh
- All product candidates are in preclinical or early clinical stages, with no approved products, making the company entirely dependent on successful clinical development [sec · filed 2026-03-12].
- The company has a history of significant losses and expects to continue incurring losses, with no guarantee of future profitability [sec · filed 2025-03-06].
- Clinical development timelines are uncertain and subject to delays due to patient enrollment, regulatory hurdles, and capital constraints [sec · filed 2026-03-12].
- The company may need substantial additional funding to complete development and commercialization, and failure to obtain capital could force delays or termination of programs [sec · filed 2025-03-06].
From the filings
Quoted directly from source documents.
Molecular Partners has no approved products and all candidates are in preclinical or clinical stages.
“All of our product candidates are in preclinical or various stages of clinical development.”
SEC filings · March 12, 2026
The company expects to continue incurring losses and may not achieve profitability.
“We have incurred significant losses since our inception, we expect to incur losses in future periods and may not achieve profitability in the upcoming years.”
SEC filings · March 6, 2025
Cash runway is estimated into 2028.
“anticipated funding through collaborations, will enable us to fund our operating expenses and capital expenditure requirements into 2028.”
SEC filings · March 12, 2026
Risks & what to watch (4)›
Key risks
- No approved products — All candidates are preclinical or early clinical; no marketing approval from FDA or other authorities [sec · filed 2025-03-06].
- History of losses — Significant losses since inception; expects continued losses and may not achieve profitability [sec · filed 2025-03-06].
- Clinical trial delays — Uncertain timelines due to patient enrollment, regulatory, and capital constraints [sec · filed 2026-03-12].
- Need for additional capital — May need substantial funding to complete development; failure could delay or terminate programs [sec · filed 2025-03-06].
What to watch
- Initiation and progress of Phase 1 clinical trial for MP0712 (DLL3 Radio DARPin Therapy) [sec · filed 2026-03-12].
- Expansion or completion of Phase 1 trial for MP0533 in AML [sec · filed 2026-03-12].
- Initiation of new clinical trial for MP0317 in combination therapies [sec · filed 2026-03-12].
- Cash burn rate and any updates to cash runway estimates beyond 2028 [sec · filed 2026-03-12].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run MOLECULAR PARTNERS AG through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MOLECULAR PARTNERS AG facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
4
Total value held
$14.2M
| Holder | Shares | Value |
|---|---|---|
| suvretta capital management, llc | 2,221,494 | $8.8M |
| bvf inc/il | 1,353,968 | $5.4M |
| smartharvest portfolios, llc | 15,543 | $62K |
| morgan stanley | 367 | $1K |
Short Interest
as of May 1, 2026- % of float
- 0.1%
- Days to cover
- 3.4
- Shares short
- 12,887
- Daily short volume (Aug 19, 2026)
- 0.9%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MOLN short interestFrequently asked questions
What is the AI investment thesis for MOLECULAR PARTNERS AG?
Molecular Partners AG is a clinical-stage biotechnology company developing a pipeline of DARPin-based targeted oncology therapeutics, including CD3 T-cell engagers and Radio DARPin Therapies, with no approved products to date.
Who is the CEO of MOLECULAR PARTNERS AG?
Dr. Patrick Amstutz Ph.D. is the chief executive officer of MOLECULAR PARTNERS AG (MOLN).
Where is MOLECULAR PARTNERS AG headquartered?
MOLECULAR PARTNERS AG (MOLN) is headquartered in Schlieren, Switzerland.
What therapeutic areas does MOLECULAR PARTNERS AG focus on?
MOLECULAR PARTNERS AG develops therapies across Oncology, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.